{"analyses":[{"ciLowerLimit":"0.86","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.69","estimateComment":"Comparison: \"Tertile 1 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2893","paramType":"Odds Ratio (OR)","paramValue":"1.20","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.61","estimateComment":"Comparison: \"Tertile 1 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy, hysterectomy, current estrogen, prior estrogen, benign breast disease.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4301","paramType":"Odds Ratio (OR)","paramValue":"1.15","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.97","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.58","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0806","paramType":"Odds Ratio (OR)","paramValue":"1.24","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.55","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy, hysterectomy, current estrogen, prior estrogen, benign breast disease.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1226","paramType":"Odds Ratio (OR)","paramValue":"1.21","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.89","estimateComment":"Comparison: \"Tertile 2 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3502","paramType":"Odds Ratio (OR)","paramValue":"1.23","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.81","estimateComment":"Comparison: \"Tertile 2 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy, hysterectomy, current estrogen, prior estrogen, benign breast disease.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4654","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.23","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3987","paramType":"Odds Ratio (OR)","paramValue":"0.86","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.20","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy, hysterectomy, current estrogen, prior estrogen, benign breast disease.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3349","paramType":"Odds Ratio (OR)","paramValue":"0.84","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.96","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.98","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0827","paramType":"Odds Ratio (OR)","paramValue":"1.38","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.96","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy, hysterectomy, current estrogen, prior estrogen, benign breast disease.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0932","paramType":"Odds Ratio (OR)","paramValue":"1.36","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.07","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.80","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0130","paramType":"Odds Ratio (OR)","paramValue":"1.39","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.04","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.75","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy, hysterectomy, current estrogen, prior estrogen, benign breast disease.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0241","paramType":"Odds Ratio (OR)","paramValue":"1.35","statisticalMethod":"Conditional Logistic Regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19468"},{"groupId":"OG001","value":"188199"}]}],"title":"Never (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"306"}]}],"title":"Tertile 1 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"182"}]}],"title":"Tertile 2 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"237"}]}],"title":"Tertile 3 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19390"},{"groupId":"OG001","value":"187532"}]}],"title":"Never (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"577"}]}],"title":"Tertile 1 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"355"}]}],"title":"Tertile 2 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"460"}]}],"title":"Tertile 3 (without 2 year lag)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19564"},{"groupId":"OG001","value":"188924"}],"units":"Participants"}],"description":"Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).","groups":[{"description":"Cases","id":"OG000","title":"Cases"},{"description":"Controls","id":"OG001","title":"Controls"}],"paramType":"NUMBER","populationDescription":"Cases \\& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.","reportingStatus":"POSTED","timeFrame":"The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.","title":"Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","type":"PRIMARY","unitOfMeasure":"participants"}